Since the introduction of chemotherapy for the treatment of childhood leukemia more than sixty years ago, the, prognosis for children with cancer has improved dramatically. The 5-year survival rate for childhood cancers, many of which were uniformly fatal in the pre-chemotherapy era, is now approaching.80%. Despite these advances, several childhood cancers still have unacceptably low cure rates, and even when treatment is successful, the acute and long-term morbidity of current therapy can be substantial. The Children's Oncology Group (COG), the world's largest organization devoted exclusively to childhood and adolescent cancer research, was founded 12 years ago. The COG's multidisciplinary research team, comprised of more than 8,000 members, conducts research at more than 200 leading children's hospitals, universities, and cancer centers. This proposal is for COG, as part of NCI's new National Clinical Trials Network, to continue its collaborative research work that supports the mission of improving the outcome for all children with cancer. The COG will design and conduct clinical-translational studies for children with cancer that builds on an increasing understanding of the molecular basis for pediatric malignancies and has the highest potential to improve the outcome. Using innovative clinical trial designs suitable for the study of rare diseases, we will study novel therapeutic approaches that range from targeted, small molecules to cellular therapies. As more than 90% of children diagnosed with cancer in the US are treated at COG member institutions, the COG has the ability to offer to children with cancer and their families to participation in research that allows for collection and annotation of biospecimens from all children with cancer, providing the foundation for discovery and accelerating the most promising research efforts conducted in laboratories around the world. The COG research portfolio importantly also includes research trials focused on improving the quality of life children with cancer and survivors. The proposal is for support of the COG Group Operations Center, clinician-scientists who develop and conduct research, and for member sites to participate through enrollment of eligible subjects.

Public Health Relevance

The Children's Oncology Group (COG) is the world's largest organization devoted exclusively to childhood and adolescent cancer research. Over 200 leading children's hospitals, universities, and cancer centers across North America participate in COG research, which is focused on developing better treatments for all children with cancer.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
3U10CA180886-01S6
Application #
8920206
Study Section
Special Emphasis Panel (ZCA1-GRB-I (O1))
Program Officer
Mooney, Margaret M
Project Start
2014-04-11
Project End
2019-02-28
Budget Start
2014-04-11
Budget End
2015-02-28
Support Year
1
Fiscal Year
2014
Total Cost
$265,465
Indirect Cost
$6,979
Name
Children's Hospital of Philadelphia
Department
Type
DUNS #
073757627
City
Philadelphia
State
PA
Country
United States
Zip Code
19104
Janitz, Amanda E; Ramachandran, Gurumurthy; Tomlinson, Gail E et al. (2017) Maternal and paternal occupational exposures and hepatoblastoma: results from the HOPE study through the Children's Oncology Group. J Expo Sci Environ Epidemiol 27:359-364
Katzenstein, Howard M; Furman, Wayne L; Malogolowkin, Marcio H et al. (2017) Upfront window vincristine/irinotecan treatment of high-risk hepatoblastoma: A report from the Children's Oncology Group AHEP0731 study committee. Cancer 123:2360-2367
Schwartz, Cindy L; Chen, Lu; McCarten, Kathleen et al. (2017) Childhood Hodgkin International Prognostic Score (CHIPS) Predicts event-free survival in Hodgkin Lymphoma: A Report from the Children's Oncology Group. Pediatr Blood Cancer 64:
Walterhouse, David O; Pappo, Alberto S; Meza, Jane L et al. (2017) Reduction of cyclophosphamide dose for patients with subset 2 low-risk rhabdomyosarcoma is associated with an increased risk of recurrence: A report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group. Cancer 123:2368-2375
Zheng, Daniel J; Lu, Xiaomin; Schore, Reuven J et al. (2017) Longitudinal analysis of quality of life outcomes in children during treatment for acute lymphoblastic leukemia: A report from the Children's Oncology Group AALL0932 trial. Cancer :
London, Wendy B; Bagatell, Rochelle; Weigel, Brenda J et al. (2017) Historical time to disease progression and progression-free survival in patients with recurrent/refractory neuroblastoma treated in the modern era on Children's Oncology Group early-phase trials. Cancer 123:4914-4923
Ward, Jessica; Swanson, Barbara; Fogg, Louis et al. (2017) Pilot Study of Parent Psychophysiologic Outcomes in Pediatric Hematopoietic Stem Cell Transplantation. Cancer Nurs 40:E48-E57
Landier, Wendy; Hageman, Lindsey; Chen, Yanjun et al. (2017) Mercaptopurine Ingestion Habits, Red Cell Thioguanine Nucleotide Levels, and Relapse Risk in Children With Acute Lymphoblastic Leukemia: A Report From the Children's Oncology Group Study AALL03N1. J Clin Oncol 35:1730-1736
Gupta, Abha A; Chi, Yueh-Yun; Anderson, James R et al. (2017) Patterns of chemotherapy-induced toxicities and outcome in children and adolescents with metastatic rhabdomyosarcoma: A report from the Children's Oncology Group. Pediatr Blood Cancer 64:
Rudzinski, Erin R; Anderson, James R; Chi, Yueh-Yun et al. (2017) Histology, fusion status, and outcome in metastatic rhabdomyosarcoma: A report from the Children's Oncology Group. Pediatr Blood Cancer 64:

Showing the most recent 10 out of 274 publications